1405
KLINICKÁ341804001074588109168189242288347
FARMAKOLOGIE709804001074291138211265312372415474533554598
A13288040010753
FARMACIE1403804001074191138210265316336380
/18298040010732
Klin190680400107446583131
Farmakol2057804001074278105179220258305325
Farm.2402804001074178104179195
2026;40(1):41-462617804001074487128170185229275299339356371414452475522568
/32308040010731
www.klinickafarmakologie.cz4568804001076513320121425327329234035839843647950254457164568672477179183988990895196610061045
461818020012657116
PŘEHLEDOVÉ341200012660124182256312369444520587645
ČLÁNKY1008200012660115187259327395
Léčiva3413600106296196114152188
ze54536001063163
skupiny62336001063166107142159200237
ARTA87636001063873105141
a1033360010638
jejich1087360010622548198133174
interakce12773600106155688120156198233266298
s1591360010630
perorálními163736001063364100141177219250291309362380
antikoagulancii203236001063879112129165204242280321352394435469487504
LITERATURA34457001234978134189250318368438498567
1.3437400853648
Koudelková,4057400833572110150184200230267299332345
M76574008354
et8337400833457
al.904740083324760
Prostascreening.cz978740083365693120143176203235256290326364379417456469501531
–152474008335
Program1573740083355693133154187245
časného18327400833164901281633438400833876
záchytu439840083286194132162187225
karcinomu684840083306384115130168207265302
prostaty1006840083396198125148181202236
[online].1262840083185593108123161196213225
Praha:1507840083355689127159172
Ústav1699840083436992125157
zdravotnických1876840083286687120343940083326991129144176206240272310
informací672940083155372109131189222254269
a96094008332
statistiky1011940083264982104119145169184214248
ČR,1278940083407589
2024.13879400833468101133145
[cit.155194008319496487100
2025-08-22].16709400833468101136158195231254284319337349
Available34310400834171104120135167206222257
from:6151040083194178136148
https://www.prostascreening.cz.7791040083375983123149162189209260313367378418439476503526559586618639673709747762800839852884914928
Verze17231040083356889120154
1.018921040083344479
2.34311400853754
Ikushima4241140083154787115155171232266
S,71711400833347
Ono79111400834989130
R,94711400833752
Fukuda102611400833372104144185219
K,127211400833652
et135111400833559
al.14371140083324963
Trousseau’s15271140083345291132160188225258298312339
syndrome:18931140083266110234312400833962101161198211
cancer-associated57812400833367107141176198219253281309349384400433456492533
thrombosis.11351240083226285124184225266294310337352
Jpn151112400832566106
J1641124008325
Clin16901240083415773113
Oncol.182712400834889122161178192
2016;46(3):204-208.34313400833468100131143178214233267284296331365401424455489525538
3.34314400853649
Khorana40314400833573110130162199230
AA,6441440083408295
Mackman75014400835486117146203234271
N,103214400834556
Falanga11001440083326074105142180211
A,132214400834054
et138714400833354
al.14531440083314557
Cancer-associated152114400834072108139172192211242267292329361375406426459497
venous34315400833265103140178203
thromboembolism.5601540083225980116174212250285342381419434449474531543
Nat11171540083457798
Rev122915400833569101
Dis13441540083456085
Primers.14431540083355570127162182209222
2022;8(1):11.16791540083346799133145180198229243254283310319
4.34316400853651
Leblanc41116400833166105121153191223
K,65116400833549
Edwards71716400833371123155177215241
SJ,9751640083325769
Dranitsaris106116400834567100138153176203236258273299
G,137716400834457
et145116400833457
al.15251640083314760
Drug160216400834567105144
Interactions1763164008315537410812916219421823434317400833776102
between4661740083397497150185220259
Androgen74517400834180119140177217252290
Receptor105617400833571103137177199236258
Axis-Targeted13341740083417490116137167196217255290312346386
Therapies174117400833272107128161201216251278
and34318400833271111
Antithrombotic47618400834180103118141181202241300340380403418451
Therapies94818400833474110132165205222257285
in125418400831554
Prostate13291840083365795123146180202237
Cancer:158718400834175114147181203217
Delphi18261840083468298138177193
Consensus.34319400834077115142177215241278305318
Cancers67719400833972110142176197225
(Basel).9171940083195487114149164184195
2024;16(19):3336.112719400833468101133145175206225257287305317352385418453466
5.34320400853650
Dai4092040083457791
C,51720400834052
Dehm58520400834680118175
SM,7762040083338799
Sharifi89220400833269101121136153170
N.107920400834457
Targeting11532040083325980117151173188225263
the14332040083215993
Androgen154220400834179117138174213247285
Signaling184320400833347851221543432140083152865103
Axis4562140083417287112
in57921400831451
Prostate6402140083355590116138169190222
Cancer.87321400833971108138171191200
J1084214008324
Clin11192140083395367103
Oncol.123321400834784115150165177
2023;41(26):4267-4278.14212140083346698131141175204218250282299310343374407438456491522554586598
6.34322400853651
Gregorová4072240083446599138176197234266299
J,71922400832436
Tašková7682240083326086116153185218
I.99822400831528
Antikoagulační103922400834179100115145182215254291306338370408423
terapie.14752240083215576109148163197210
Praha:16972240083355689127159171
Maxdorf;1881224008354861173432340083387698119133
2022.49123400833569102136149
7.34324400853645
American40124400834199134155171203236274
Cancer68824400834073111143177198
Society.90024400833371104119153176209219
Cancer113324400834073111143177198
Facts13452440083326294118146
&1504244008340
Figures15572440083334887124145179206
2024.177724400833468101133146
Atlanta:1936244008341623432540083154785107139152
American51025400834199134155171203236274
Cancer79925400834073111143177198
Society;101225400833371104119153176209223
2024.125025400833468101133145
8.34326400853652
Chen41326400834078113151
Y,58226400833544
Zhou64426400833876114152
Q,81426400834761
Hankey89326400834577115145179211
W,112226400835867
et120826400833456
al.12822640083324760
Second136126400833267100137175214
generation159426400833873111146167200222237275314
androgen1926264008332703432740083385996136171209
receptor5672740083215587121160182219241
antagonists8232740083327091124163201240255281304332
and117027400833270109
challenges129427400833169101116132166204243278305
in161427400831553
prostate16822740083386097124147180202235
cancer19322740083326434328400833870103125
treatment.4832840083224377109131189224262283297
Cell7952840083407489105
Death91528400834580112134172
Dis.11032840083456087100
2022;13(7):632.121828400833569102136149179209227261281293328362395407
9.34329400853649
Soumarová40629400833271109167199220257289322
R.74229400833550
Onkologie.80529400834786116154170208247262297309
Praha:11282940083355689127159171
Univerzita13132940083448196129163184215231253286
Karlova,16132940083346889105143175208221
nakladatelství1848294008337691001161483433040083387092126141167191225241
Karolinum;5993040083356990127143158196233291303
2025.91730400833569102136148
10.3433140085367085
Tran4453140083335083121
C,58431400834053
Ouk65531400834785115
S,78831400833346
Clegg8523140083405590129168
NJ,10383140083457082
et113831400833456
al.12123140083324860
Development129131400834580112147162200240298333371393
of170231400833757
a1777314008331
second-generation1826314008327629413117034332400833860101136174209230263285300338377
antiandrogen7353240083327092107139177216237274314349387
for11383240083185677
treatment12313240083214377109131189224262283
of153032400833757
advanced160232400833271104137175207241280
prostate189832400833860973433340083264982104138
cancer.49633400833164102134168189199
Science.7113340083326580114152185218230
2009;324(5928):787-790.95733400833468104139152187220252271304337370404422434467500533552583617652665
11.3433440085366678
Souhrn43634400833271109147168207
údajů65834400833776108124161
o835344008337
přípravku8873440083396076115136169201232270
(SPC)11723440083195085126146
–1334344008335
Xtandi;13843440083385991129168184195
2025159534400833468101136
12.3433540085366884
Clegg4443540083405590129168
NJ,6313540083446982
Wongvipat73135400835794132171204220259292313
J,106335400832436
Joseph11173540083246289124163202
JD,13373540083247081
et143635400833457
al.15113540083324760
ARN-509:158935400834177123145179213249262
a1869354008332
novel1919354008337763433640083326682
antiandrogen4393640083327091106138176215237274313348386
for8403640083185677
prostate9313640083396198125148181202236
cancer118136400833264102135168190
treatment.13853640083214377109131189224262283297
Cancer169636400834073111143177198
Res.19083640083357097111
2012;72(6):1494-503.34337400833468100130142175209227260278290320351384420443477511544557
13.3433840085366883
de44438400833873
Vries5353840083365672106133
R,68638400833650
Jacobs7543840083245688125165191
F,96438400833238
Mannens102038400835487125163198236262
G,130138400834357
et137638400833456
al.14503840083324760
Apalutamide152838400834181114129167189222280295334369
Absorption,1915384008341803433940083266485125146162199237250
Metabolism,60539400835589111144183221237252277335347
and96539400833169108
Excretion10853940083336596117151173188225264
in136139400831552
Healthy142639400834479110125147185216
Men,165439400835489127139
and180639400833269108
Enzyme19273940083326934340400832862121156
Reaction51340400833570102134159174212250
in77740400831553
Human84440400834482140172210
Hepatocytes.106840400834479118151173210243276301335362375
Drug145740400834667106145
Metab161640400835489112144184
Dispos.18144040083456187126165191205
2019;47(5):453-464.34341400833468100130143178210226260278290324357390412449485521534
14.3434240085366883
Duran43842400834583104136174
I,62442400831527
Carles6644240083407293108143169
J,84642400832436
Bulat8944240083357388119141
I,104742400831527
et108742400833456
al.11554240083324759
Pharmacokinetic122742400833572104125182214246283313329366401423438469
Drug-Drug170942400834566104143165211232270309
Interaction3434340083155274107128161193217232270308
of66443400833756
Apalutamide,73343400834180113128165188220278293332366378
Part11244340083356788112
1:124943400833442
Clinical13044340083405570107122154187202
Studies15194340083325391130145179206
in173843400831452
Healthy180343400834479110125148186216
Men34344400835490128
and48444400833270109
Patients6064440083356789104139177198226
with8454440083516689127
Castration-Resistant9854440083407399122144177199214252290313350385412427453476509547568
Prostate15664440083355693120143176198232
Cancer.181144400834072110143176198208
Clin3434540083405570108
Pharmacokinet.46645400833573105126185217249286317333371406428442
2020;59(9):1135-1148.92345400833468101135148183215235267285297327354384417439470498529565578
15.3434640085366984
Moilanen44846400835594110126158197233271
AM,74046400834298112
Riikonen873464008336526798136175211249
R,114346400833651
Oksala121546400834779108142157190
R,142646400833650
et149746400833558
al.15754640083334862
Discovery16584640083466188121158191226248282
of196146400833858
ODM-201,34347400834692146169199233264272
a628474008331
new-generation67247400833771122143183218255290310343364379416454
androgen113947400833169107128164203238275
receptor14264740083215487120158180216237
inhibitor16764740083145289104142157179216237
targeting192547400832254753434840083387395111148187
resistance544484008321558296122146178216249282
mechanisms84048400835792125163195233248274332358
to121248400832158
androgen128448400833270109130167207242280
signaling-directed157748400832641801181501661812182572803203353563904233434940083225595
prostate4534940083396098124148180202236
cancer70449400833164102134168189
therapies.9094940083216095116149188203238265279
Sci12034940083326580
Rep.129849400833570110122
2015;5:12007.143649400833468100130140175186216246280316349355
16.3435040085366984
Zurth4395040083377394118156
C,60850400833952
Koskinen6725040083357298128144181215253
M,93850400835467
Fricke1017504008332526798128162
R,119150400833549
et125250400833456
al.13205040083324759
Drug-Drug139250400834566104142164211232270308
Interaction17135040083145273106127160191215230267305
Potential3435140083357294127166187202234250
of60751400833857
Darolutamide:6795140083457798136152189212244302317356391404
In109751400831553
Vitro1165514008335527496133
and131351400833169109
Clinical14365140083405570108123155188203
Studies.16545140083335492131146181207221
Eur18905140083326990
J1995514008324
Drug34352400834567105144
Metab50352400835489111144183
Pharmacokinet.70252400833572105126184217249286316333371406428441
2019;44(6):747-759.115952400833468100130143177214234267285297330361393411443475508519
17.3435340085366876
Shore43753400833270109130164
N,61953400834558
Zurth6955340083377495120158
Ch,8715340083407890
Fricke9795340083335268100130164
R,116153400833549
et122853400833456
al.13025340083324760
Evaluation13805340083336598113151183205220258296
of169453400833757
Clinically17695340083405570108123155188203218250
Relevant3435440083367187122155188227248
Drug-Drug61254400834668107146169216238277317
Interactions9495440083155475110131165197222237276314341
and131154400833270110
Population144254400833572112151167199221237275314
Pharmacokinetics1777544008335731061271862193435540083316899115153188210226258285
of64855400833756
Darolutamide7245540083457798135151189211244302317356391
in113455400831553
Patients12065540083356789104139177199226
with14525540083506688126
Nonmetastatic159855400834583121179214236269296319352374389421
Castration-Resistant3435640083397298120141174195210247285307344378404419444467499537558
Prostate9135640083355592118141173194227
Cancer:115356400833971109140173194208
Results13735640083356996132147169196
of158256400833755
Pre-Specified16505640083355588111142180215247262279296330369
and34357400833270109
Post4715740083357299122
Hoc61257400834483115
Analyses74757400834179111127158185220247
of101457400833756
the10905740083215994
Phase120457400833572105131166
III13905740083143045
ARAMIS145457400834177120176191223
Trial.1697574008332496597112125
Target18425740083326081120154177
Oncol.34358400834786118155171184
2019;14(5):527-539.54258400833468100130143173204224257275287323356389407441474508519
18.3435940085366985
Danila44259400834578116131146178
DC,6345940083458699
Morris74759400835493114136152178
MJ,9385940083558193
de104459400833973
Bono113159400833574112151
JS,12955940083245669
et137859400833456
al.14485940083314760
Phase152159400833673105132167
II170159400831530
multicenter1745594008357951101331481802142523436040083225577
study4366040083265087127158
of61160400833757
abiraterone6846040083327187108141163196218255293328
acetate10296040083326498120153175208
plus12546040083395492118
prednisone13896040083396094134172187213251290325
therapy17306040083226095116149189220
in196660400831553
patients3436140083397293109143181203231
with5906140083516689127
docetaxel-treated73461400833876109142165197229263278301323345379411432466506
castration-resistant12566140083316491114135168190205243282304326360387402428451484522544
prostate1816614008339619812414818034362400832255
cancer.41462400833164102134168189199
J629624008324
Clin6686240083405570108
Oncol.79162400834786118155171184
2010;28(9):1496-501.99062400833468100132145180213232265283295324356389424448482516547557
19.3436340085366982
Han44263400834476114
CS,5746340083397386
Patel6776340083356789123138
R,83363400833549
Kim89963400833551109
IY.10256340083155159
Pharmacokinetics,110163400833673105126185217249286317333371406429444476503517
pharmacodynamics16356340083387710913018922125329033036234364400833870128143175202
and56464400833270109
clinical692644008331466199114146179194
efficacy905644008334527088120153185219
of114264400833857
abiraterone12186440083317186107140162196217254293328
acetate15646440083326498120153175209
for17916440083195678
treating188864400832143771093436540083223775114
metastatic47765400835792114147174197229251267298
castration-resistant7956540083316491114135168190205243282304326360387402428451484522544
prostate13586540083396198125148180202236
cancer.161465400833164102134168189199
Expert183365400833265105140161186
Opin34366400834787102140
Drug49966400834567105144
Metab65866400835590112145184
Toxicol.8576640083336797113145182198210
2015;11(6):967-975.108366400833468100130141171198213247265277312347380399434466499511
20.3436740085357085
Montgomery44067400835491128149186223280314335368
RB,8206740083357082
Vessella9146740083356793119153168183214
R,114067400833548
Mostaghel120067400835491117139171209246280295
E,150767400833245
et156467400833355
al.16316740083314658
Maintenance17016740083548610013715819122825929634368400833165
of42368400833756
intratumoral494684008315537496129150188246284306339354
androgens86368400833270109130168207242280306
in118468400831553
metastatic125268400835792114147174197230251267299
prostate15656840083396198125148181202236
cancer:181668400833164102134168189203
a343694008332
mechanism39069400835792125163195233249275332
for7386940083185677
castration-resistant8316940083316490113135168189205243281304326360387401428451483522543
tumor138969400832260118156178
growth.15826940083385997148172210224
Cancer182169400834073111143177198
Res.2138740083357097111
2008;68(11):4447-4454.22647400833468104140152188223242274302316328362399436468487524561593629641
21.2138840085356880
Ando22318400834078116154
T,23978400833241
Nishiyama2450840083445984121136167200256288
T,27508400833341
Takizawa2803840083336089105134167216249
I,30648400831527
et31038400833455
al.3171840083314659
Dihydrotestosterone3242840083456097127165185222243276302325361387410443464500538572
synthesis2138940083265997119157192219234260
pathways2411940083387193131182214245272
from2696940083194178136
inactive2845940083155385117141157189223
androgen30819400833270109130167207242280
5α-androstane-3374940083347193126164203224261288311344382417440
-3β,17β-diol21381040083215290101131160196219258273310326
in247610400831552
prostate25401040083385996122145177198231
cancer278410400833163100132165186
cells:2982104008331647994119131
Inhibition31261040083145189103142157179194231269
of340710400833756
intratumoural347510400831552739412614818524227931721381140083205368
3β-hydroxysteroid22191140083347193132162200221257287321347370403424461476515
dehydrogenase274611400833872110140178199236275309347379405439
activities31981140083326387102134150172187221247
by345811400833869
abiraterone.3540114008331708510613816019321425121381240083387385
Sci22381240083336580
Rep.233312400833671110122
2016;6:32198.247112400833468100131143179191227259291321356369
22.21381340085357186
Li223713400833146
R,229513400833548
Evaul23561340083326395132147
K,251513400833549
Sharma257613400833269101121179210
KK,27981340083357185
et289513400833455
al.29621340083324759
Abiraterone30331340083417995115147169202222259296331
inhibits33761340083145189103142157178206
3β-hydroxysteroid3594134008333719313116119821381440083215888122149172206227264280319
dehydrogenase:247614400833873111141180201238278313351383410445457
a2952144008332
rationale3003144008320537591129167199215249
for32711440083195678
increasing33681440083155385106140172198213251290
drug36771440083385998137
exposure213815400833465105144170208229263
in241415400831452
castration-resistant24791540083316491114135168190205243281304326360387402428451483521543
prostate30351540083396097124147180202235
cancer.328315400833264102134168189200
Clin34961540083395570107
Cancer361615400834073111143177198
Res.21381640083357097111
2012;18(13):3571-3579.226416400833468100130142173204223254284301313348381415447466498531565598609
23.21381740085367286
Acharya223717400834171109141161195227
M,247717400835367
Bernard25561740083357090128160181218
A,278717400834054
Gonzalez285317400834482120148181196231260
M,312517400835467
et320417400833456
al.32721740083324759
Open-label,334417400834685120158180196227266301316328
phase368517400833876108213818400832661
I,221418400831527
pharmacokinetic225618400833977109130189221253290321337375410433448480
studies27501840083275088127142177203
of296818400833757
abiraterone30391840083327187108141163196218255293328
acetate33821840083326498120153174208
in360518400831452
healthy36721840083377210412021381940083215988
men.223819400835791128141
Cancer239119400833971108140172193
Chemother259619400833976110167204226263297317
Pharmacol.292619400833471102123180211243279294306
2012;69(6):1583-1590.32441940083346798127139174207225258275287316345378411432462492523558570
24.21382040085367186
Souhrn224020400833271109147168207
údajů246220400833776108124161
o2639204008337
přípravku26912040083396076115136169201232270
(SPC)29762040083195085126146
–3138204008335
Zytiga;31882040083386792108146179191
2025.339420400833468101136148
25.21382140085367287
Büchler224121400833573105143159194215
T.247121400833342
Klinická25282140083355267105120152182215
onkologie.275921400833775105143159197236252286298
Praha:30732140083355689127159171
Maxdorf;326021400835487118156194216237251
2023.352721400833468101136148
26.21382240085367187
Ferri22422240083326688109125
N,238322400834557
Colombo24562240083407793131190229268
E,274022400833245
Tenconi280122400833364102134171209224
M,304122400835568
et312522400833456
al.31972240083324860
Drug-Drug327322400834667106145167214236274313
Interactions3602224008315537410812916219421382340083223775113140
of229623400833756
Direct23702340083456182116149173
Oral256123400834768101117
Anticoagulants269623400834179100116148184217256294309342380401429
(DOACs):314323400831864112152191219236248
From34092340083325289148
Pharmacological35742340083357310512618521721382440083316884122161176208241257
to240824400832158
Clinical24792440083405570108123155187203
Practice.26952440083355588120145160192225237
Pharmaceutics.294524400833573105126184217249282320343358390417431
2022;14(6):1120.338924400833468101136148178209228261280291321349379413425
27.21382540085367078
Vahanian222925400833566103135172187218256
A,249725400834154
Beyersdorf256425400833569100134154181220257278299
F,287525400833238
Praz29252540083355588117
F,305425400833238
et310425400833355
al.31722540083314659
202132432540083346799130
ESC/EACTS338625400833265105131165207245280313
Guidelines37112540083448121382640083155388104119157192219
for23772640083185677
the24752640083216095
management259026400835789127160199234292327365386
of299626400833857
valvular30732640083326580113151166199220
heart331326400833873104126150
disease.34832640083385480115147173208220
Eur37242640083326990
Heart213827400834479111132157
J.231027400832437
2022;43(7):561-632.236227400833468101136148183216234268288300335369400418455489522534
28.21382840085367288
Arachchillage22412840083416295127165198236251266281313352387
DJ,26422840083466880
Platton27362840083355082104128165204
S,295428400833345
Hickey30142840083445991121155187
K,321528400833549
et327928400833456
al.33492840083324760
Guidelines34242840083438196135170186201239274301
on373928400833775
the21382940083215994
investigation22442940083155283117143166181219251272287325362
and261929400833169107
management273929400835789126158196231288323360381
of313329400833756
antiphospholipid32012940083326990105144182219246284322360375390429444482
syndrome.3696294008325579621383040083385996155190202
Br235530400833657
J2427304008324
Haematol.246730400834476111169201223260276289
2024;205(3):855-880.277130400833469101133145180214248266300317329363397430452488523559571
29.21383140085367285
Lee223831400833166101
AY,23533140083417280
Levine24483140083316597113151186
MN,2648314008355100113
Baker27753140083356899133154
RI,29433140083355164
et302131400833456
al.30913140083324861
Low-molecular-weight316631400833168119142200239255289322360375407429448500535550589627648
heparin213832400833873112145167182221
versus23793240083326688115153179
a2579324008332
coumarin263132400833169107165198219235273
for29243240083195778
the30233240083226095
prevention31393240083396095127161200221237275314
of347332400833857
recurrent35513240083205588126147169203241263
venous213833400833266104143181207
thromboembolism23663340083226081119177217256291349389428444459485543
in292933400831553
patients30033340083387293109144182203231
with32553340083516689127
cancer.340333400833164102134168190200
N3624334008344
Engl368933400833371110125
J2138344008324
Med.217734400835590130143
2003;349(2):146-153.233534400833468104138149184219252272306323335365396432456487517550562
30.21383540085367287
Meyer224235400835490121155177
G.243535400834458
Comparison250935400834077135174207229244270309347
of287235400833857
low-molecular-weight294535400831553104127185224240275307345360393414433485520535574612633
heparin359535400833772111144165181219
and213836400833269108
warfarin225936400835083104125158179194232
for25043640083185577
the25943640083215994
secondary27013640083266093129168206238259293
prevention30073640083386093125159197219234271310
of332936400833757
venous339836400833266104142180206
thromboembolism36163640083226081118176213837400833876110166204242257271296352
in250237400831451
patients25653740083387091105139176196223
with28003740083496486123
cancer:293437400833163100131163184197
a3142374008332
randomized31853740083215389127164221235263296335
controlled353137400833167104125145181196211244283
study.21383840083264987126158168
Arch23223840083416293131
Intern24683840083155374108129168
Med.265138400835590130143
2002;162(15):1729-1735.280938400833468104137150180211244262293323342354383413447481505536565599632644
31.21383940085366981
Lee224039400833166101
YJ,23613940083355668
Park24503940083356788118
J-K,2588394008325488499
Uhm270739400834482140
J-S,2867394008324477891
et297839400833456
al.30553940083314760
Bleeding31353940083355186121161176214253
risk3408394008321366292
and352139400833169108
major365039400835789105143164
adverse213840400833271104138159186221
events237540400833467101139161188
in257940400831553
patients26484040083397293109143182203231
with28954040083506689127
cancer303840400833164102134168189
on324340400833776
oral33354040083375992107
anticoagulation3458404008332709210713917620924828630133321384140083223775113
therapy.22674140083216095116149188219229
Int25124140083145274
J2601414008324
Cardiol.26414140083407294132147185201214
2016;203:372-378.287041400833468100131143178212246257292324359379411443477490
32.21384240085356985
Giustozzi22354240083435895120143179206237252
M,249942400835467
Agnelli257842400834178115149165179194
G,278442400834356
Del28524240083457994
Toro-Cervera29594240083326586122145187220241275308329361
J,333242400832436
et338042400833355
al.34474240083314659
Direct35184240083456080114145169
Oral369942400834668100115
Anticoagulants213843400834179101116148185218257294310342380402429
for25874340083195678
the26854340083226095
Treatment28004340083325084116137196231269290
of311043400833857
Acute318743400834172110133166
Venous337343400833669107145183210
Thromboembolism36034340083327293130188213844400833977113171210249265280306364
Associated25214440083416995133166181213235269308
with28484440083516689127
Cancer:299444400834073111143177198212
A3225444008341
Systematic32854440083326289112146204236258273305
Review361044400833570102118153204
and213845400833270109
Meta-Analysis.226045400835590112145167208247279294326353368394408
Thromb26814540083337293130188228
Haemost.292245400834476111169208234257271
2020;120(7):1128-1136.320645400833468101135148178208242262296316328358385415449472502530560594608
33.21384640085367186
Sabatino224146400833265105138159175213251
J,250846400832436
De256146400834580
Rosa265846400833573100133
S,280746400833346
Polimeni28694640083357288103160195234249
A,313446400834155
et320546400833457
al.32784640083324760
Direct33544640083466182116149173
Oral354346400834769102118
Anticoagulants367746400834179100116213847400833168101140178193225263285313
in246647400831452
Patients25334740083356789104139177199226
With27744740083587496134
Active29244740083407296111144178
Cancer:311747400834073111143177198212
A3344474008341
Systematic34004740083326289112146204236258273305
Review37204740083367121384840083314680129
and227948400833168106
Meta-Analysis.239748400835387109141162202239270285316342356381394
JACC280348400832462100137
CardioOncol.29524840083397192128143180227264295331346359
2020;2(3):428-440.33224840083346799132144178194227243255288319352374409445480492
34.21384940085367388
Raskob22404940083356895124162201
GE,24544940083447790
van255749400833265103
Es267349400833260
N,274649400834557
Verhamme28164940083366990128161218276311
P,314049400833540
et319349400833456
al.32624940083324760
Edoxaban333549400833371109139172211244282
for36304940083185677
the37204940083226095
Treatment21385040083324983114136193228265286
of243750400833756
Cancer-Associated250550400834072110141175195215255283309347379394425447480519
Venous303750400833567105143180206
Thromboembolism.32555040083337292129187225264299356395433449463489546559
N2138514008345
Engl219851400833370109125
J2338514008324
Med.237851400835489129142
2018;378(7):615-624.253551400833468100131143178210244263297317329364395425447484517549562
35.21385240085367085
Agnelli223652400834178116151166181195
G,244452400834357
Becattini251352400833570102135156180195233247
C,277352400834052
Meyer283852400835489120154174
G,302552400834357
et309452400833456
al.31625240083324760
Apixaban32345240083418095126158197229267
for35145240083185576
the36035240083215994
Treatment37095240083324983213853400833254112147185206
of235853400833757
Venous242853400833669107145183210
Thromboembolism26515340083337293131189228267302360400438454469495553
Associated32185340083416995133166181213235269308
with35405340083516689127
Cancer.3681534008340721102138544008331658696
N2250544008344
Engl231054400833270109125
J2450544008324
Med.248954400835590129143
2020;382(17):1599-1607.264754400833468101135148183217251268300329349361391421453488512543574609642648
36.21385540085367288
Górnicki224255400834482104143158190220236
T,249455400833241
Bułdyś25515540083357389128160187
K,275455400833549
Zielińska28195540083385388103118156182212246
D,308055400834556
et315255400833456
al.32245540083324760
Direct-Acting33005540083456182116148173192233265289304342381
Oral369755400834769102117
Anticoagulant213856400834179100115147183216255292307339377398
Therapy254956400833271106127160199230
in279156400831553
Cancer285656400834073110142176197
Patients-A30655640083356788104138176197225245286
Review.336456400833570102118152203213
Cancers359056400834072110142175196223
(Basel).21385740083195487114149165184195
2023;15(10):2697.234857400833468101136147178208225257288307319354387421454460
37.21385840085367079
Kraaijpoel22325840083355790123138153192231266282
N,252858400834558
Carrier26005840083397293115131166187
M.280158400835468
How288358400834483134
I3031584008314
treat30595840083224378109131
cancer-associated320458400833164102134168189209241268294333365381413434468508
venous372658400833165213859400833876114140
thromboembolism.22945940083215980118176215254290347387426441456483540553
Blood.28635940083355189128167180
2019;133(4):291-298.305959400833468100130143173203236254287304316351385417436467501536550
38.21386040085367287
Hindley22386040083445996135150184215
B,246660400833547
Lip25266040083314685
GYH,262360400834479124136
McCloskey277260400835486127142179206235269300
AP,30846040083417681
et317760400833456
al.32456040083324760
Pharmacokinetics331760400833572104125183214246283313329366401423438469497
and213861400833269108
pharmacodynamics225861400833876108129187219250287326357396427484499531558
of282961400833655
direct28976140083385273107139163
oral30726140083375891106
anticoagulants.31906140083326991106137174206245282297328366387414428
Expert363061400833265104139159184
Opin213862400834787102140
Drug229462400834567105144
Metab245362400835590112145184
Toxicol.26526240083336797113145182198210
2023;19(12):911-923.287862400833468101136147177207227258288306318353385413431466500534547
39.21386340085367185
Souhrn223863400833271109147168207
údajů246063400833776108124161
o2637634008337
přípravku26896340083396076115136169201232270
(SPC)29746340083195085126146
–3136634008335
Pradaxa;31866340083355689128160192224236
2025343863400833468101136
40.21386440085367489
Byon224664400833567105143
W,240864400835867
Garonzik24946440083447697135173202218248
S,276164400833245
Boyd282564400833573105143
RA,29876440083357892
et309864400833456
al.31726440083324861
Apixaban:32516440083418096127160199232270282
A3552644008341
Clinical36116440083405570108123155188204
Pharmacokinetic213865400833573105126184217249286316333371406428443475
and263165400833270109
Pharmacodynamic275865400833573105126184217249286325357396428486501533
Review.330965400833671103119153204215
Clin35426540083405570108
Pharmacokinet.366865400833573105126213866400835790122159189206244279301314
2019;58(10):1265-1279.246866400833468100130143178212231263294312324354384418451474504534567601612
41.21386740085366981
Souhrn223567400833271109147168207
údajů245767400833776108124161
o2634674008337
přípravku26866740083396076115136169201232270
(SPC)29716740083195085126146
–3133674008335
Eliquis;31836740083334863101139154180192
2025.339167400833468101136148
42.21386840085367085
Kvasnička22366840083356496122160175206235268
T,251768400833241
Malikova257068400835486101116146183214247
I,282968400831527
Zenahlikova286968400833770108140177192207236273305337
Z,321968400833750
et328268400833355
al.33506840083314659
Rivaroxaban34216840083355183115136173203235274306344
–3780684008334
Metabolism,213869400835490112145184223239254280337350
Pharmacologic250869400833572105126184217249286302340379394426
Properties29546940083355693133168190214230264291
and326569400833270109
Drug339469400834567105144
Interactions.3558694008314527410812916219421823439347400833776102116
Curr4065740083407698119
Drug42007400834567105144
Metab.43597400835590112145184197
2017;18(7):636-642.45717400833468100129139169200219254273285321355389412450486519531
43.3934840085367186
Souhrn40368400833271109147168207
údajů42588400833776108124161
o443584008337
přípravku4487840083396076115136169201232270
(SPC)4772840083195085126146
–493484008335
Xarelto;4984840083387092126141164201213
2025.52128400833468101136148
44.3934940085367490
Souhrn40399400833271109147168207
údajů42619400833776108124161
o443894008337
přípravku4490940083396076115136169201232270
(SPC)4775940083195085126146
–493794008335
Lixiana;498794008331477893125163196208
2025.52109400833468101136148
45.39341040085367186
Mar403310400835487108
PL,41541040083356679
Gopinathannair424610400834483122138175208229267299337375407423444
R,470210400833650
Gengler476510400834378116155171205227
BE,50041040083366982
et509910400833456
al.51681040083324760
Drug524110400834567105144
Interactions5398104008314527410712816119339341140083213673110136
Affecting40821140083405877110142165180217255
Oral43491140083466799113
Anticoagulant44741140083417898113144180212250286301332369390
Use.487611400834368102113
Circ50011140083395474104
Arrhythm51171140083406182119149173210266
Electrophysiol.53951140083324781112136156192393412400833977108135150188204216
2022;15(6):e007956.416612400833468101136148178208226259277289324359395428461496530543
46.39341340085367489
Souhrn403913400833271109147168207
údajů426113400833776108124161
o4438134008337
přípravku44901340083396076115136169201232270
(SPC)47751340083195085126146
–4937134008335
Warfarin498713400835789110131165186201239
Orion;52421340083476884122160172
2025.543013400833468101136148
47.39341440085367079
Shatzel402614400833270102124154188204
JJ,42431440083244860
Daughety431514400834678115154192227249282
MM,4610144008354109123
Olson47451440083476389127166
SR,49231440083336882
et501714400833456
al.50861440083324760
Management515914400835487124157195230288323361382
of555414400833756
Anticoagulation393415400834179101116148185218257294310342364379417455
in440615400831553
Patients44761540083356789104138177198226
With47191540083577396134
Prostate48701540083355693119143175197231
Cancer511815400834073111143176198
Receiving533315400833570103136151184200238277
Enzalutamide.393416400833370100133149186209241299314353388400
J4350164008324
Oncol438916400834786118155171
Pract.45751640083355689121145158
2017;13(11):720-727.474916400833468100129139169199217249276291303336370404428460494527533
48.39341740085367490
Otsuka40371740083477198136166199
Y,424917400833544
Poondru430617400833572110149188209247
S,456717400833245
Bonate462517400833574112144166200
PL,48381740083356680
et493117400833456
al.50011740083314760
Physiologically-based50741740083357210313014518319923727629232435637238741944148151439341840083266099
pharmacokinetic404518400833976108129186218249286316332369403425440471
modeling452818400835795134168183198235273
to481318400832258
predict48831840083396093132147178202
drug-drug50971840083385896134156196216254292
interaction5402184008314517210512615819039341940083223775113
of406519400833756
enzalutamide413819400833472102135151188211243301316355390
with45451940083516789127
combined468919400833269127166182220255294
P-gp50001940083355797136
and515319400833270109
CYP3A528019400833977113147187
substrates.54841940083266310239342040083264971104125159186200
J4149204008324
Pharmacokinet418820400833673105126185217249286317333371406429
Pharmacodyn.463220400833572105126184217249286325357396409
2023;50(5):365-376.505720400833468101136147182216236269288300335369403425458490522535
49.39342140085357083
Lennep402921400833164101138172211
BW,425221400833491100
Mack436421400835485116146
J,452221400832435
Poondru456921400833570108146184204242
S,482321400833244
et487921400833355
al.49462140083314658
Enzalutamide:50162140083326998130145182203235292306344378390
Understanding54182140083438011815217339342240083264982120159174212251
and420322400833270109
Managing433022400835487125157196211249288
Drug463622400834567105144
Interactions47982240083155374108129162194219234272310337
to515322400832158
Improve522922400831573112133171202237
Patient5484224008335678810439342340083347294
Safety40432340083326584119141175
and423323400833270109
Drug435723400834667106145
Efficacy.4517234008332506886118151183217227
Drug475923400834567105144
Saf.4919234008332658495
2024;47(7):617-641.503023400833468101133144179211228262282294329359389407445481511521
50.39342440085367389
Steffel40442440083335589109129164180
J,424524400832437
Collins43032440083407895110126164191
R,451524400833651
Antz458724400834180103134
M,474224400835569
et483224400833558
al.49112440083324861
2021499324400833570104136
European51502440083337092130170207239278
Heart544924400834581114135161
Rhythm393425400833574104129167225
Association41732540083406895133166181213235250288326
Practical45132540083355689121145160192225240
Guide47672540083438297136170
on495125400833776
the50402540083226095
Use514825400834470105
of526625400833756
Non-Vitamin533625400834483121144179196218251393426400835772110
K4059264008335
Antagonist410926400834179101133172211249264290313
Oral443726400834769102117
Anticoagulants456926400834179101116148185218257295310342380402429
in501326400831553
Patients50812640083356788104138177198226
with53222640083506688126
Atrial5463264008341628499131147
Fibrillation.39342740083324786108124139154186208223261300313
Europace.42622740083336990128167200232266278
2021;23(10):1612-1676.455627400833468101132140175210228260291310322351383413443463494525558590603
51.39342840085367082
Gibbons40312840083445998138177215241
JA,42872840083256479
de438128400833872
Vries44682840083365672107134
M,461628400835568
Krauwinkel46992840083355891128179195233263297313
W,502728400835767
et510928400833456
al.51802840083324760
Pharmacokinetic52552840083357210512618421724928631633339342940083387395110142
Drug408929400834567105144
Interaction42462940083155375108130163195219234272311
Studies45702940083325391130145180207
with47902940083516689127
Enzalutamide.49302940083327099133148186208241299314353388400
Clin53432940083405570108
Pharmacokinet.546429400833573105126393430400835790122159189206244279301314
2015;54(10):1057-1069.426430400833468100130140176211230262293312324353385419452471502533569603614
52.39343140085367085
Parrett40323140083356687108142164188
JL,42323140083245669
Reaves431331400833570101132166192
AB,45183140083407688
Self46193140083326682100
TH,47323140083327790
et483431400833456
al.49023140083324759
Enzalutamide-warfarin49743140083326998131146183205237294309348382405456488509530563583599636
interaction39343240083145273106126159190214228266303
necessitating425032400833771103136162188202224256278292329368
warfarin463032400835082103124156177192229
dosage487132400833875101134172206
adjustment:50903240083316984121147169226261298319332
A5434324008341
case54873240083316389123
report39343340083215594133154179
of412633400833756
successful41953340083276496127160187214234272288
clinical4496334008331466199114146179194
management.470333400835890128160199234292327365387400
J5116334008324
Clin51533340083405570108
Pharm527433400833573105126184
Ther.547233400833271106128138
2018;43(2):276-279.393434400833468100131143178211229263280292328360392416447480513524
53.39343540085367287
Casserly404335400834074101128164186202235
EA,42993540083337691
Rogers441135400833675115151172200
SE,46323540083336680
Keisner47333540083357086113151187209
SV.49633540083337080
Lack50643540083326699130
of521535400833757
interaction52933540083155476110132166199223239278317
between39343640083397496150184219258
enzalutamide420736400833473102135151188211244301317355390
and461336400833270109
warfarin473836400835183105126159181196234
in498836400831553
a5056364008332
metastatic510436400835893115148174197230252267299
castration-resistant5419364008331649111413516839343740083223775113136158192219234260283316354375
prostate43273740083386097124147180201235
cancer458037400833164102134168189
patient.47863740083397294109144182203217
J5020374008324
Oncol506237400834785117154170
Pharm525037400833572105126184
Pract.54523740083355588121145158
2017;23(1):68-70.393438400833468100129139174209227259273285320356379410443456
54.39343940085367388
Potdar40403940083357294132164185
R,424339400833549
Gartrell43103940083447798122144178193209
BA,45363940083367791
Given46453940083435991126164
R,482739400833549
et489439400833456
al.49683940083324760
Concomitant504639400834077115148185243258280313351373
use54373940083376398
of555339400833757
oral39344040083375992107
anticoagulants40554040083327092107139176209248285301333371393420
in448940400831553
patients45564040083397293109143181203231
with48014040083506688126
advanced494140400833271104137175207241280
prostate52354040083396198125148181202236
cancer54854040083316410239344140083316586
receiving40344140083215587121136169185222261
apalutamide:430941400833271104120157180213270286324359372
A4695414008341
post-hoc474941400833978105128147186225257
analysis502041400833270102118150177191218
of525141400833857
TITAN53224140083324983120165
and550141400833270109
SPARTAN393442400833267105140174211257
studies.42064240083264987126141176203217
Am443842400834199
J4552424008324
Cancer459242400833972110143176197
Res.48054240083357097111
2022;12(1):445-450.493142400833468101136148178208225257272283318355388410446479513526
55.39344340085367185
Souhrn403543400833271109147168207
údajů425743400833776108124161
o4434434008337
přípravku44864340083396076115136169201232270
(SPC)47714340083195085126146
–4933434008335
Erleada;49834340083335369104136175207219
2025.521843400833468101136148
56.39344440085367288
Podgoršek404244400833572111150189210237272303
E,436444400833346
Mehra443044400835489127149182
N,463144400834558
van470944400833164102
Oort483144400834786107132
IM,49834440083146983
et508644400833356
al.51624440083314760
Clinical52414440083405570108123155188204
Pharmacokinetics546444400833573105126393445400835790122159189206244279301316348376
and432945400833270109
Pharmacodynamics445745400833572105126184217249286325357396428486501533561
of503745400833757
the51134540083215994
Next522645400834580112136
Generation53814540083447911715217420739344640083223775113
Androgen406746400834179118139176216251289
Receptor437546400833570103137176198235257
Inhibitor-Darolutamide.46514640083155391106145161183220242261308341362399415452475508565581619654667
Clin53374640083405570108
Pharmacokinet.546446400833573105126393447400835790122159189206244279301314
2023;62(8):1049-1061.426447400833468101136147183216233267285297327358395428451482514549580589
57.39344840085367180
Boujonnier403348400833574112127165204242257291313
F,436448400833238
Lemaitre442148400833165123155171193214249
F,468848400833238
Scailteux47444840083336598113128151185222254
LM.501648400833187101
Pharmacokinetic513548400833573105126185217249286317333371406428444476
Interactions39344940083155375108130163195219235273312338
Between42934940083357093146181216254
Abiraterone,45684940083418196117151172206228265304339351
Apalutamide,493949400834181114130167190223281296335370382
Darolutamide53424940083457799136152190212245393450400835772110145
or409150400833759
Enzalutamide41625040083337099132147184207239296311350384
and455950400833169108
Antithrombotic467950400834179100115137175196233290329368389404436
Drugs:512750400834567105143169181
Prediction53215040083355589128143175198213251289
of393451400833757
Clinical40065140083395570107123154187203
Events42245140083326498136158186
and442551400833169109
Review454951400833570102118153204
of476851400833756
Pharmacological483951400833573105126185217249286302340380395427460475
Information.5329514008315537210913118922224325939345240083377689
Cardiovasc40385240083407394132147185217250277309
Drugs436252400834667106145171
Ther.454852400833372107128139
2024;38(4):757-767.470252400833468101133145180214233266284295329361395413445477509516
58.39345340085367288
Souhrn403853400833271109147168207
údajů426053400833776108124161
o4437534008337
přípravku44895340083396076115136169201232270
(SPC)47745340083195085126146
–4936534008335
Nubeqa;498653400834582121157196229241
2025.524253400833469101136148
59.39345440085367184
Benoist403454400833571109147162188212
GE,42625440083437790
Hendriks436854400834479117156177193223252
RJ,46365440083356274
Mulders472654400835492107146181202230
PFA,497254400833567105119
et510754400833456
al.51795440083324760
Pharmacokinetic52555440083357310512618521724928631733339345540083377294109141
Aspects408755400834169107143175199226
of432655400833756
the43955540083215994
Two450155400833379117
Novel463155400834482114148163
Oral480755400834668101116
Drugs493555400834667105144170
Used511755400834469104143
for52735540083185577
Metastatic53625540083548911114417019322539345640083213668
Castration-Resistant40155640083397298121142174196211248286308345379406420446469501539560
Prostate45885640083355592118141173195228
Cancer:482956400833972109141174195208
Abiraterone50505640083418095116148170203224261299333
Acetate539656400834071105127159180214
and393457400833168107
Enzalutamide.40535740083326997130145182203235292307345379390
Clin44565740083395468105
Pharmacokinet.457357400833571103123181212244280310325362397418431
2016;55(11):1369-1380.50165740083346798129140175206223254281295307336365398431454484514547582594
60.39345840085367590
Monbaliu404558400835594134174207223239277
J,434358400832437
Gonzalez440158400834484123153187203239269
M,469158400835569
Bernard47815840083367293133166188227
A,502958400834156
et510658400833457
al.51845840083324861
In526658400831554
Vitro5341584008336537698136
and549858400833371111
In393459400831553
Vivo40085940083355285122
Drug-Drug415159400834567106145167215236275314
Interaction44865940083145374108130163195219235273312
Studies48185940083335492131147181208
to504759400832259
Assess51265940083427096131158185
the53325940083216095
Effect54485940083325170105138162
of393460400833860
Abiraterone402660400834284102125160184220243282323361
Acetate,441960400834276112136171195231245
Abiraterone,469660400834284102125160184220243283323361374
and510360400833373115
Metabolites525060400835694118153195236254270295331360
of393461400833859
Abiraterone401661400834283100122157179215237276316353
on439261400833878
CYP2C8449361400834280119154195231
Activity.474761400834376101117151168192227238
Drug500861400834769109150
Metab518161400835693116151192
Dispos.53966140083466390131172200214
2016;44(10):1682-1691.393462400833468100131143178215235266298316328358389424458478509540574606616
61.39346340085366981
Dubinsky403663400834584123139177203233267
S,432463400833245
Thawer439063400833272104155190211
A,462163400834156
McLeod469763400835587119153192232
AG,49496340083418498
et506763400833457
al.51446340083324861
Management522563400835587125158197232290325363385
of393464400833757
anticoagulation40046440083327091107139175208248285300333354370408446
in446464400831452
patients45306440083387193108143181203230
with47746440083506688126
metastatic491464400835792115147174197230252267299
castration-resistant522664400833264911141361691902062442823043263613934654008326416790123161183
prostate41336540083396198124148180202236
cancer438665400833164102134168189
receiving45926540083205487121136168184222261
abiraterone48706540083327186107140162196217254293328
+5215654008341
prednisone.52736540083396094134172187213251290325337
Support393466400833270109149187209234
Care41836640083407394128
Cancer.432666400834073111143177198208
2019;27(9):3209-3217.455066400833468100130143178211227260278290325357391427450483515546576582
62.39346740085367187
Mithoowani40356740083547092131169208259291329344
S,439367400833245
Tan44516740083336199
CW,456367400834099109
Siegal46856740083334882122154169
DM.4868674008345100114
Measuring499567400835590122148185207222260299
Direct53076740083466182116149173
Oral549367400834769102118
Anticoagulant393468400834179101116148185218257294310342380402
(DOAC)435068400831864113152191212
Levels:45766840083316698132148174186
Applications,477668400834181120136151183216238253291329356369
Limitations,515968400833147105120142175197212250288315328
and550168400833270109
Future39346940083326991129150184
Directions.41346940083456182116148173188226264291304
Int44546940083145274
J4543694008324
Lab458369400833164104
Hematol.470269400834479137169191228244257
2025497469400833469101136
Apr512669400834180101
22.52436940083346981